IL2 and Sjogren syndrome: In previous studies, the effectiveness of low-dose IL-2 on Treg cell proliferation and disease remission in psoriatic arthritis (PsA) (46), systemic lupus erythematosus (SLE) (47), and Sjögren’s syndrome (SS) (48) has been demonstrated, but side effects have not been evaluated.